BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass
Related Questions
What is the status of the company's pipeline and any upcoming product launches that could drive future sales?
What were the gross margin and operating margin for the quarter, and are there any trends indicating margin compression or expansion?
Is the write‑off a one‑off event or indicative of a broader issue with credit collection that could affect future receivables?
How does CareDx's Q2 revenue growth rate compare to its main competitors in the transplant‑diagnostics space?
What is the cash balance and burn rate post‑quarter, and does the company have adequate liquidity to fund its growth initiatives?
How will the $86.7 million Q2 revenue compare to analyst expectations and consensus estimates?
Did management provide guidance for Q3 or FY 2025, and how does that guidance influence the stock valuation?
What is the expected effect of the $3.8 million aged‑receivables write‑off on the company's net income and cash flow?
How has the market reacted to the release so far, and what volume and price trends are emerging in real‑time trading?
Are there any changes to the capital‑return policy (share repurchases or dividends) that could impact investor sentiment?